| Literature DB >> 35499000 |
Audry Peredo-Lovillo1, Adrián Hernández-Mendoza2, Belinda Vallejo-Cordoba2, Haydee Eliza Romero-Luna1.
Abstract
The interest for food-derived bioactive peptides, either from common or unconventional sources, has increased due to their potential therapeutic effect against a wide range of diseases. The study of such bioactive peptides using conventional methods is a long journey, expensive and time-consuming. Hence, bioinformatic approaches, which can not only help to predict the formation of bioactive peptides from any known protein source, but also to analyze the protein structure/function relationship, have gained a new meaning in this scientific field. Therefore, this review aims to provides an overview of conventional characterization methods and the most recent advances in the field of in silico approaches for predicting and screening promising food-derived bioactive peptides.Entities:
Keywords: Food-derived proteins; Gastrointestinal digestion; Proteolytic enzymes; Structural characteristics
Year: 2021 PMID: 35499000 PMCID: PMC9039911 DOI: 10.1016/j.fochx.2021.100183
Source DB: PubMed Journal: Food Chem X ISSN: 2590-1575
Conventional and unconventional sources of bioactive peptides from food-derived proteins.
| Peptides Source | Protein substrate | Peptide(s) | Obtaining method | Bioactivities | References |
|---|---|---|---|---|---|
| Dairy products | Buffalo cheese | Water-soluble peptides | Fermentation | Antimicrobial against | da |
| Prato cheese | β-CN (f193-209) | Fermentation by | Inhibitory activity of the ACE (90.22% after 120 days of ripening). | ||
| Parmigiano-Reggiano cheese | β-CN fractions | Ripening time and enzymatic digestion, and | ACE-inhibitory, anti-hypertensive, antimicrobial, immunomodulatory, antioxidant, dipeptidyl peptidase IV-inhibitory (DPP-IV), and anxiolytic peptides identified in the literature using Milk Bioactive Peptides Database (100% homology) | ||
| Goat milk | AFPEHK | Fermentation by | ACE-inhibitory of 10 kDa permeates (25.16 %) | ||
| Camel milk | 3 kDa and 10 kDa fractions | Fermentation by | ACE-inhibitory (76.75% after 48 h of fermentation with | ||
| Buffalo milk | αS1-CN variant AA | Enzymatic digestion | ACE-inhibitory, anticancer, antioxidant, and anxiolytic (predicted by BIOPEP). | ||
| Meat | Cooked beef | IVAPGKGILAADESTGSIAK | ACE-inhibitor, antithrombotic, antiamnestic, DPP-IV inhibitor (predicted by BIOPEP). | ||
| Duck meat | < 5 kDa fractions | Post-mortem aging | Antioxidant assessed at 3 days of aging by DPPH (59.83%), FRAP (greater than 300 μM FeSO4⋅7H2O Eq/g sample), and ORAC (1000 μMTEq approximately) | ||
| Pork, beef, chicken, and turkey meat | < 3 kDa fractions | Antioxidant activity evaluated with ABTS (594.9, 535.2, 714.3, and 651.9 μmol Trolox/g of peptide of beef, chicken, pork, and turkey, respectively), ACE-inhibitory (IC50 from 81.2 μg/mL (chicken) to 238.0 μg/mL (Turkey)), and DPP- IV (IC50 from1.88 mg peptides/mL (pork) to 2.71 mg peptides/mL (chicken)) | |||
| Fish | Fish skin gelatin | Glycopeptides | Enzymatic hydrolysis with alcalase and flavourzyme, and then glycosylated | Antimicrobial activity against | |
| Tilapia skin collagen | GPAGPAGEK, DGPSGPKGDR, GLPGPSGEEGKR, and DGPSGPKGDRGETGL | Enzymatic hydrolysis with trypsin, pepsin, neutral protease, alkaline protease and protamex | Iron-chelating (83.47% at a hydrolysate concentration of 5 mg/mL) | ||
| Other animal products | Egg white | Egg white peptides | Enzymatic hydrolysis | Calcium-chelating (44.1 mg of calcium/kg). | |
| Cereals | Wheat gluten proteins | YYP, IP, YVP, YP | Opioid peptides identified using BIOPEP database | ||
| Maize | 19ZP1, 19ZP2 and 19ZP3 | ACE-inhibitory (IC50 from 14.19 to 202.04 μM) and antioxidant evaluated by ORAC (from 9.47 to 1349.36 μM TE/g of peptide) | |||
| Brown rice | FGGSGGPGG and FGGGGAGAGG | Enzymatic hydrolysis with bromelain | ACE-inhibitory (IC50 value of 0.20 mg protein/mL). | ||
| Quinoa | QHPHGLGALCAAPPST | Enzymatic hydrolysis by bromelain, chymotrypsin, and Pronase E | DPP-IV ( | ||
| Legumes | Soy milk | 10 kDa fraction | Fermentation by | Antioxidant evaluated by ABTS (1831 TEAC μm) and DPPH (50.74% of inhibition) and ACE-inhibitory (73.35% of ACE inhibition) | |
| Black beans | SGNGGGGGASM, SKPGGGSPVA, VELVGPK, KPTTGKGALA | DPP-IV and ACE inhibitors peptides identified using BIOPEP database. | ( | ||
| Pea | YSSPIHIW, ADLYNPR, and HYDSEAILF. | Enzymatic hydrolysis | Antioxidant evaluated by PeptideRanker (scores from 0.53 to 0.74) | ||
| Algae | Red seaweed | GGSK and ELS | Enzymatic proteolysis | α-amylase inhibitory (IC50 of 2.58 mM and 2.62 mM for GGSK and ELS, respectively) | ( |
| EYFDALA | Enzymatic hydrolysis using pepsin | Antioxidant evaluated by ABTS and DPPH (IC50 11.07 μg/mL and 4.83 μg/mL, respectively, with a molar concentration of 13.4 μmol/mL of peptide). | |||
| Plant | Yam ( | < 3.5 kDa fractions | Antioxidant (value close to 80% of DPPH radical scavenging), ACE-inhibition (IC50 of 90 μg/mL), and antimicrobial (MIC of 0.094 mg/mL against | Do Nascimento et al., 2021 | |
| Edible rhizomes (turmeric, and ginger) | VTYM (ginger), CGVGAA, DVDP, and CACGGV (turmeric). | Enzymatic hydrolysis by pepsin and trypsin | Antioxidant evaluated by DPPH (EC50 = 19.9 μmol/L for VTYM), and ABTS (EC50 = 24.0 μmol/L for VTYM), and ACE-inhibition (IC50 = 16.4, 18.3, 19.0, and 25.0 μmol/L for VTYM, CGVGAA, DVDP, and CACGGV, respectively). | ||
| Edible insects | FDPFPK | Baked and | Antioxidant evaluated by DPPH (EC50 = 0.35 mg/mL), ABTS (EC50 = 0.08 mg/mL), and anti-inflammatory by lipoxygenase inhibitory activity (LOX, IC50 = 2.85 mg/mL) and Cyclooxygenase 2 inhibitory activity (COX 2, IC50 = 7.40 mg/mL). | Zielińska, Baraniak, & Karas, 2018. | |
| IIAPPER | Antioxidant evaluated by DPPH (EC50 = 1.01 mg/mL), ABTS (EC50 = 15.62 mg/mL), and anti-inflammatory by LOX (IC50 = 8.21 mg/mL) and COX 2 (IC50 = 8.16 mg/mL). | ||||
| AGDDAPR | Antioxidant evaluated by DPPH (EC50 = 1.83 mg/mL), ABTS (EC50 = 1.89 mg/mL), and anti-inflammatory by LOX (IC50 = 7.03 mg/mL) and COX 2 (IC50 = 9.01 mg/mL). | ||||
| Cricket protein hydrolysates (60–85% of degree of hydrolysis) | Enzymatic hydrolysis with alcalase and enzymatic digestion | ACE inhibition (IC50 from 0.062 to 0.066 mg/mL) | |||
| Food industry waste | Meat myofibrillar proteins | Acidic peptides (fractions 6–10) | Enzymatic proteolysis with a bacterial-derived protease | Antioxidant evaluated by ORAC (above 12 mmol/L TE). | |
| Fish muscle ( | 5.3 kDa fraction | Enzymatic proteolysis with protease produced by | Antioxidant evaluated by DPPH (20% of radical inhibition) and ABTS (above 15 % of radical inhibition). | ||
| Tofu whey wastewater | Lunasin | Tofu processing | Anti-inflammatory and immunomodulatory, assessed using RAW 264.7 murine macrophages (30% reduction of TNF-α with 190 μM lunasin). | ||
| Spent coffee grounds | YGF and GMCC | Fermentation process by | ACE and DPP-IV inhibitors obtained using BIOPEP database and classified by PeptideRanker (score of 0.97) | ||
| Spent brewer yeast | SPQW, PWW and RYW | Autolysis and enzymatic hydrolysis | ACE-inhibition (IC50 = 84.2 μg/mL) and antioxidant evaluated by ORAC (IC50 from 5.5 to 7.25 μg/mL) | Amorim et al., 2019b | |
| Microorganisms | Edible cyanobacterium | ACE and DPP-IV inhibitors (39.1 and 47.7 % of peptides from cyanobacterium, respectively) obtained using BIOPEP database | |||
| LPESVHLDK, VLSTSFPPLK | Sonicated-enzymatic hydrolysis (trypsin and chymotrypsin) | Antioxidant (IC50 = 5568 μM TE/mg protein for VLSTSFPPLK) and ACE-inhibition (IC50 = 22.88 and 15.20 μM for LPESVHLDK and VLSTSFPPLK, respectively). | |||
| Fungi | 25 novel antioxidant peptides | Enzymatic hydrolysis by neutral protease | Antioxidant evaluated by the total antioxidant capacity assay (0.73 μmol TE/mg). | ||
| Edible mushroom ( | Ultrafiltered fractions (1–3 kDa) | Enzymatic hydrolysis by alcalase and pancreatin | Antioxidant evaluated by FRAP (0.62 of absorbance at 3 mg/mL) | ||
| Mushroom protein hydrolysates (65% of hydrolysis degree) | Enzymatic hydrolysis by proteinase K | Antioxidant evaluated by DPPH (IC50 = 5.24 mg/mL), ABTS (IC50 = 1.80 mg/mL), and hydroxy radical (IC50 = 1.09 mg/mL), and ACE inhibitory (87%) at 10 mg/mL. | |||
Controlled parameters in enzymatic hydrolysis for obtaining bioactive peptides.
| Enzyme/ substrate ratio (% w/w) | pH | Temperature | Hydrolysis time (min) | Identified peptides | Protein substrate —Bioactivity | Reference(s) |
|---|---|---|---|---|---|---|
| Pepsin | ||||||
| 1 | 2 | 37 | 120 | No identified | Deer velvet — ACE-inhibitory (17.57% ACE activity) | |
| Pancreatin | ||||||
| 4 | 7.5 | 37 | 120 | No identified | Deer velvet — ACE-inhibitory (17.57% ACE activity) | |
| Chymotrypsin | ||||||
| 1 | 7.8 | 50 | 360 | QHPHGLGALCAAPPST and other 34 peptides identified | Quinoa — ACE-inhibitory (IC50 = 0.22 mg/mL) and DPP-IV inhibitory (IC50 = 0.72 mg/mL) | |
| Papain | ||||||
| 0.5 – 4 | 6.0 – 7.0 | 37 – 50 | 40 – 480 | No identified in most investigations; 22 peptides containing the LPF tripeptide (Corn Gluten Meal). | Camel whey — Antibacterial activity against | |
| Bromelain | ||||||
| 1 – 100 | 5.0 – 7.0 | 40 – 50 | 180 – 420 | No identified in most investigations; 7 peptides containing the LPF tripeptide (Corn Gluten Meal); APAAIGPYSQAVLVDR and other 34 peptides (Porcine liver); FGGSGGPGG, FGGGGAGAGG and other 6 peptides (Brown rice) | Porcine Liver — antioxidant activity evaluated by DPPH (from 322 to 379 μg Trolox/g), FRAP (from 57.2 to 69.8 μmol Fe2+/100 g), ABTS (from 280 to 335 mg ascorbic acid/100 g), and ORAC (from 31.5 to 36.4 mg Trolox/g), and antibacterial activity against | |
| Ficin | ||||||
| 22.5 | 6.0 | 50 | 240 | LLPFYQ and QQILLPF | Corn Gluten Meal — antioxidant activity evaluated by DPPH (greater than 60% of radical scavenging with 5 mg/mL of hydrolysates) | |
| Flavourzyme | ||||||
| 1 | 5.5 | 50 | 420 | APAAIGPYSQAVLVDR and other 34 peptides | Porcine Liver — peptides with antioxidant activity identified by SWATH and correlated with antioxidant capacity. | |
| Alcalase | ||||||
| 1 – 3 | 8.0 | 50 | 240–480 | No identified | Porcine Liver — antioxidant activity evaluated by DPPH (from 443 to 562 μg Trolox/g), FRAP (from 43.3 to 82.9 μmol Fe2+/100 g), ABTS (from 761 to 1068 mg ascorbic acid/100 g), and ORAC (from 35.8 to 53.2 mg Trolox/g), and antimicrobial activity against | |
Fig. 1Hybrid approach for the generation of new bioactive peptides from food-derived proteins. Conventional methods consist of a series of in vitro studies. First, the protein source is subjected to an in vitro hydrolysis with an enzyme selected according to its known specificity. Afterward, the hydrolysates are assessed by in vitro tests for the bioactivity of interest. Then the peptides are identified and can be synthesized or separated by molecular weight (fractions). Subsequently, the in vitro bioactivity is evaluated again in the peptide previously identified. In case of finding positive results, a promising new peptide should be validated through ex vivo and in vivo studies and, finally carry out clinical trials. While the in silico approach consists of a series of bioinformatics methodologies. Previously known proteins of interest are downloaded from a database (e.g., UniProt), to be loaded into specialized databases on BP (e.g., BIOPEP), where hydrolysis can be performed with different enzymes at the same time. As a result, peptides are obtained, which are evaluated using computational tools to predict their bioactivity (e.g., PeptideRanker), allergenicity (e.g., AlgPred), and toxicity (e.g., ToxinPred). After data analysis, important information can be obtained that indicates the way forward (i.e., proper selection of proteins and enzymes to obtain BP) and, in the case of hybrid approach, these conditions are replicated by in vitro hydrolysis, but also within this approach can synthesize peptides and follow conventional strategies. Subsequently, molecular docking is carried out, where the interaction between peptides and receptor molecules of interest is predicted. However, it has been highlighted that these interactions must be verified by conventional methods, in order to generate a new BP by a hybrid approach. Once the product has been evaluated through in vivo studies followed by clinical studies, products with the new peptides and proven benefits are marketed.